Smoking Cessation After Initial Treatment Failure With Varenicline or Nicotine Replacement: A Randomized Clinical Trial.

What Was Tested

The paper reports a study of Therapeutic nicotine (patch, non-peptide), published as a randomized controlled trial.

To determine the best subsequent strategy for nonabstinence following initial treatment with varenicline or combined nicotine replacement therapy (CNRT).

Why It Was Studied

Most people who smoke do not quit on their initial attempt.

Who Took Part

The study group was 490 volunteers.

The age groups tagged for this paper are middle-aged adults, both men and women.

Using a double-blind, placebo-controlled, sequential multiple assignment randomized trial, 490 volunteers were randomized to receive 6 weeks of varenicline or CNRT.

The study was conducted from June 2015 through October 2019 in a Texas tobacco treatment clinic.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Because people in this Therapeutic nicotine (patch, non-peptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Therapeutic nicotine (patch, non-peptide) study, the assignments were hidden from both participants and investigators until the end.

Some volunteers received a placebo instead of Therapeutic nicotine (patch, non-peptide), giving a reference point.

What Was Measured

PubMed files the paper under topics including Nicotine, Nicotinic Agonists, Smoking Cessation, Smoking Cessation Agents, Treatment Failure, Varenicline and White.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Therapeutic nicotine (patch, non-peptide) in 490 volunteers.

With several hundred people or more, it is a fairly large study for this kind of research.

Results are reported in around 9 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2024 (JAMA), a journal based in United States.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.